Recap: Jaguar Health Q2 Earnings

3
3
Favorite

Recap: Jaguar Health Q2 Earnings

Benzinga2021-08-13

Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).

Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.

Guidance

Jaguar Health hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Aug 13, 2021

Time: 08:00 AM

ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039

Recent Stock Performance

Company's 52-week high was at $4.47

52-week low: $0.18

Price action over last quarter: Up 8.87%

Company Profile

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（3）

2020TS
·2021-08-14
wait til 1.15-1.10
Reply
Like
Report
cart158
·2021-08-13
Time to buy now? How?
Reply
1
Report
Cheahmanda
·2021-08-13
Ok
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2159829435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-13 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2159829435","market":"us","top_or_hot":-1,"title":"Recap: Jaguar Health Q2 Earnings","media":"Benzinga","content":"<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recap: Jaguar Health Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecap: Jaguar Health Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-13 19:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAGX","symbol_name":"Jaguar Animal Health, Inc.","start_time":0,"source_url":null,"article_id":"2159829435","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2159829435","pubTimestamp":1628852688,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" \n\nShares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\n\nQuarterly Results\n\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"translate_title":"回顾：捷豹健康第二季度收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAGX":0.9},"content_text":"Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).\nRevenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.\nGuidance\nJaguar Health hasn't issued any earnings guidance for the time being.\nRevenue guidance hasn't been issued by the company for now.\nDetails Of The Call\nDate: Aug 13, 2021\nTime: 08:00 AM\nET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039\nRecent Stock Performance\nCompany's 52-week high was at $4.47\n52-week low: $0.18\nPrice action over last quarter: Up 8.87%\nCompany Profile\nJaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":897947246,"gmtCreate":1628871166385,"gmtModify":1676529882880,"author":{"id":"3568580098685907","authorId":"3568580098685907","name":"2020TS","avatar":"https://community-static.tradeup.com/news/11248151fdcb83034da72e0a80b4d0ae","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568580098685907","authorIdStr":"3568580098685907"},"htmlText":"wait til 1.15-1.10","listText":"wait til 1.15-1.10","text":"wait til 1.15-1.10","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/897947246","repostId":2159829435,"repostType":2,"repost":{"id":"2159829435","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628852688,"share":"https://ttm.financial/m/news/2159829435?lang=&edition=fundamental","pubTime":"2021-08-13 19:04","market":"us","language":"en","title":"Recap: Jaguar Health Q2 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2159829435","media":"Benzinga","summary":" \n\nShares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\n\nQuarterly Results\n\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).","content":"<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recap: Jaguar Health Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecap: Jaguar Health Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-13 19:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159829435","content_text":"Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).\nRevenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.\nGuidance\nJaguar Health hasn't issued any earnings guidance for the time being.\nRevenue guidance hasn't been issued by the company for now.\nDetails Of The Call\nDate: Aug 13, 2021\nTime: 08:00 AM\nET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039\nRecent Stock Performance\nCompany's 52-week high was at $4.47\n52-week low: $0.18\nPrice action over last quarter: Up 8.87%\nCompany Profile\nJaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894740335,"gmtCreate":1628859995827,"gmtModify":1676529877286,"author":{"id":"3556954148323654","authorId":"3556954148323654","name":"cart158","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":1,"idStr":"3556954148323654","authorIdStr":"3556954148323654"},"htmlText":"Time to buy now? How?","listText":"Time to buy now? How?","text":"Time to buy now? How?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894740335","repostId":2159829435,"repostType":4,"repost":{"id":"2159829435","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628852688,"share":"https://ttm.financial/m/news/2159829435?lang=&edition=fundamental","pubTime":"2021-08-13 19:04","market":"us","language":"en","title":"Recap: Jaguar Health Q2 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2159829435","media":"Benzinga","summary":" \n\nShares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\n\nQuarterly Results\n\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).","content":"<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recap: Jaguar Health Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecap: Jaguar Health Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-13 19:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159829435","content_text":"Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).\nRevenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.\nGuidance\nJaguar Health hasn't issued any earnings guidance for the time being.\nRevenue guidance hasn't been issued by the company for now.\nDetails Of The Call\nDate: Aug 13, 2021\nTime: 08:00 AM\nET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039\nRecent Stock Performance\nCompany's 52-week high was at $4.47\n52-week low: $0.18\nPrice action over last quarter: Up 8.87%\nCompany Profile\nJaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894791130,"gmtCreate":1628854206420,"gmtModify":1676529875394,"author":{"id":"3575348507224102","authorId":"3575348507224102","name":"Cheahmanda","avatar":"https://static.tigerbbs.com/85933c7123d4b95f87fbba0cd7951e7f","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575348507224102","authorIdStr":"3575348507224102"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894791130","repostId":2159829435,"repostType":4,"repost":{"id":"2159829435","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628852688,"share":"https://ttm.financial/m/news/2159829435?lang=&edition=fundamental","pubTime":"2021-08-13 19:04","market":"us","language":"en","title":"Recap: Jaguar Health Q2 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2159829435","media":"Benzinga","summary":" \n\nShares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\n\nQuarterly Results\n\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).","content":"<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recap: Jaguar Health Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecap: Jaguar Health Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-13 19:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>Jaguar Health</b> (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.</p>\n<h2>Quarterly Results</h2>\n<p>Earnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).</p>\n<p>Revenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.</p>\n<h2>Guidance</h2>\n<p>Jaguar Health hasn't issued any earnings guidance for the time being.</p>\n<p>Revenue guidance hasn't been issued by the company for now.</p>\n<h2>Details Of The Call</h2>\n<p>Date: Aug 13, 2021</p>\n<p>Time: 08:00 AM</p>\n<p>ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&amp;tp_key=b3a06aa039</p>\n<h2>Recent Stock Performance</h2>\n<p>Company's 52-week high was at $4.47</p>\n<p>52-week low: $0.18</p>\n<p>Price action over last quarter: Up 8.87%</p>\n<h2>Company Profile</h2>\n<p>Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JAGX":"Jaguar Animal Health, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2159829435","content_text":"Shares of Jaguar Health (NASDAQ:JAGX) moved higher by 1.5% in pre-market trading after the company reported Q2 results.\nQuarterly Results\nEarnings per share rose 77.27% year over year to ($0.10), which missed the estimate of ($0.03).\nRevenue of $385,000 declined by 87.84% from the same period last year, which missed the estimate of $7,280,000.\nGuidance\nJaguar Health hasn't issued any earnings guidance for the time being.\nRevenue guidance hasn't been issued by the company for now.\nDetails Of The Call\nDate: Aug 13, 2021\nTime: 08:00 AM\nET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1487163&tp_key=b3a06aa039\nRecent Stock Performance\nCompany's 52-week high was at $4.47\n52-week low: $0.18\nPrice action over last quarter: Up 8.87%\nCompany Profile\nJaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":3,"commentSize":3,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}